Clyde Thornsberry

Clyde Thornsberry's AcademicInfluence.com Rankings

Clyde Thornsberry

Philosophy

#6058

World Rank

#9025

Historical Rank

Logic

#3252

World Rank

#4380

Historical Rank

philosophy Degrees

Clyde Thornsberry

Biology

#8212

World Rank

#11253

Historical Rank

Microbiology

#414

World Rank

#467

Historical Rank

biology Degrees

Download Badge

Philosophy
Biology

Clyde Thornsberry's Degrees

Doctorate Medicine University of California, San Francisco

Why Is Clyde Thornsberry Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Clyde Thornsberry's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Trends in Antimicrobial Resistance among Urinary Tract Infection Isolates of Escherichia coli from Female Outpatients in the United States (2002) (411)
Surveillance for Antimicrobial Susceptibility among Clinical Isolates of Pseudomonas aeruginosa and Acinetobacter baumannii from Hospitalized Patients in the United States, 1998 to 2001 (2003) (395)
Multidrug-Resistant Urinary Tract Isolates ofEscherichia coli: Prevalence and Patient Demographics in the United States in 2000 (2001) (375)
In Vitro Antibacterial Properties of Pexiganan, an Analog of Magainin (1999) (318)
Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in the United States, 1997-1998. (1999) (302)
Emerging resistance among bacterial pathogens in the intensive care unit – a European and North American Surveillance study (2000–2002) (2004) (296)
Halophilic Vibrio species isolated from blood cultures (1976) (289)
Comparison of the E Test to agar dilution, broth microdilution, and agar diffusion susceptibility testing techniques by using a special challenge set of bacteria (1991) (287)
The role of beta-lactamase in staphylococcal resistance to penicillinase-resistant penicillins and cephalosporins (1986) (278)
Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002 (2004) (262)
Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group. (1997) (254)
Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae (1985) (251)
Successful use of broth microdilution in susceptibility tests for methicillin-resistant (heteroresistant) staphylococci (1983) (245)
Epidemiology and antibiotic susceptibility of bacteria causing skin and soft tissue infections in the USA and Europe: a guide to appropriate antimicrobial therapy. (2003) (223)
Antimicrobial susceptibility of vancomycin-resistant Leuconostoc, Pediococcus, and Lactobacillus species (1990) (218)
Regional trends in antimicrobial resistance among clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States: results from the TRUST Surveillance Program, 1999-2000. (2002) (217)
Antimicrobial susceptibility patterns of common and unusual species of enterococci causing infections in the United States. Enterococcal Study Group (1992) (210)
Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid (1984) (195)
Rapidly growing mycobacteria: testing of susceptibility to 34 antimicrobial agents by broth microdilution (1982) (183)
Factors associated with relative rates of antimicrobial resistance among Streptococcus pneumoniae in the United States: results from the TRUST Surveillance Program (1998-2002). (2003) (173)
National collaborative study of the prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae (1988) (169)
Survey of Susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Isolates to 26 Antimicrobial Agents: a Prospective U.S. Study (1999) (165)
Prevalence of gyrA, gyrB, parC, and parE Mutations in Clinical Isolates ofStreptococcus pneumoniae with Decreased Susceptibilities to Different Fluoroquinolones and Originating from Worldwide Surveillance Studies during the 1997-1998 Respiratory Season (2000) (164)
Trends in Antimicrobial Susceptibilities among Enterobacteriaceae Isolated from Hospitalized Patients in the United States from 1998 to 2001 (2003) (140)
Ampicillin Resistance in Haemophilus influenzae as Determined by a Rapid Test for Beta-Lactamase Production (1974) (139)
Antimicrobial resistance of pneumococci in children with acute lower respiratory tract infection in Pakistan (1991) (134)
Factors Associated with Relative Rates of Antibiotic Resistance in Pseudomonas aeruginosa Isolates Tested in Clinical Laboratories in the United States from 1999 to 2002 (2004) (127)
New recommendations for disk diffusion antimicrobial susceptibility tests for methicillin-resistant (heteroresistant) staphylococci (1984) (126)
Need for Annual Surveillance of Antimicrobial Resistance in Streptococcus pneumoniae in the United States: 2-Year Longitudinal Analysis (2001) (126)
Antimicrobial Susceptibility Patterns of Common and Unusual Species of Enterococci Causing Infections in the United States (124)
Antimicrobial susceptibility testing of Francisella tularensis with a modified Mueller-Hinton broth (1985) (123)
Resistance surveillance of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in Asia and Europe, 1997-1998. (2000) (123)
Methods of measuring zones of inhibition with the Bauer-Kirby disk susceptibility test (1979) (116)
Cefotaxime: a review of in vitro antimicrobial properties and spectrum of activity. (1982) (115)
Activity of daptomycin against susceptible and multidrug-resistant Gram-positive pathogens collected in the SECURE study (Europe) during 2000-2001. (2003) (113)
Antimicrobial Susceptibility of Haemophilus influenzae (1974) (111)
Screening pneumococci for penicillin resistance (1986) (109)
Laboratory Evaluation of a Rapid, Automated Susceptibility Testing System: Report of a Collaborative Study (1975) (108)
Prevalence of antimicrobial resistance among urinary tract pathogens isolated from female outpatients across the US in 1999. (2001) (106)
Bacterial resistance and therapeutic outcome following three months of topical acne therapy with 2% erythromycin gel versus its vehicle. (2002) (103)
Susceptibility to fluoroquinolones among commonly isolated Gram-negative bacilli in 2000: TRUST and TSN data for the United States. Tracking Resistance in the United States Today. The Surveillance Network. (2002) (101)
Quality control limits for ampicillin, carbenicillin, mezlocillin, and piperacillin disk diffusion susceptibility tests: a collaborative study (1981) (101)
In vitro activities of azithromycin (CP 62,993), clarithromycin (A-56268; TE-031), erythromycin, roxithromycin, and clindamycin (1988) (100)
Evaluation of Current Activities of Fluoroquinolones against Gram-Negative Bacilli Using Centralized In Vitro Testing and Electronic Surveillance (2001) (99)
Prevalence of antimicrobial resistance among clinical isolates of Haemophilus influenzae: a collaborative study. (1986) (97)
Broth-Dilution Method for Determining the Antibiotic Susceptibility of Anaerobic Bacteria (1975) (90)
In-vitro studies of meropenem. (1989) (90)
Comparative Surveillance Study of Telavancin Activity against Recently Collected Gram-Positive Clinical Isolates from across the United States (2008) (89)
Susceptibility of antimicrobial-resistant urinary Escherichia coli isolates to fluoroquinolones and nitrofurantoin. (2003) (89)
In Vitro Activity of Antimicrobial Agents on Legionnaires Disease Bacterium (1978) (87)
Ceftazidime, a pseudomonas-active cephalosporin: in-vitro antimicrobial activity evaluation including recommendations for disc diffusion susceptibility tests. (1981) (86)
In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates (1984) (83)
Review of in vitro activity of third-generation cephalosporins and other newer beta-lactam antibiotics against clinically important bacteria. (1985) (82)
Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin (1985) (81)
Rifampin: spectrum of antibacterial activity. (1983) (77)
In vitro evaluation of three new macrolide antimicrobial agents, RU28965, RU29065, and RU29702, and comparisons with other orally administered drugs (1983) (76)
Baseline Study To Determine In Vitro Activities of Daptomycin against Gram-Positive Pathogens Isolated in the United States in 2000-2001 (2003) (75)
Antimicrobial activity of desacetylcefotaxime alone and in combination with cefotaxime: evidence of synergy. (1982) (75)
Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem. (2004) (74)
Inoculum standardization in antimicrobial susceptibility testing: evaluation of overnight agar cultures and the Rapid Inoculum Standardization System (1983) (73)
Effect of Temperature on the In Vitro Susceptibility of Staphylococcus aureus to Penicillinase-Resistant Penicillins (1973) (73)
In vitro antimicrobial activity of cefoperazone, cefotaxime, moxalactam (LY127935), azlocillin, mezlocillin, and other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase-producing strains (1980) (72)
Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies. (2005) (71)
Clinical laboratory evaluation of the Abbott MS-2 automated antimicrobial susceptibility testing system: report of a collaborative study (1980) (71)
Standardization of disk diffusion and agar dilution susceptibility tests for Neisseria gonorrhoeae: interpretive criteria and quality control guidelines for ceftriaxone, penicillin, spectinomycin, and tetracycline (1989) (69)
Characteristics of coagulase-negative staphylococci that help differentiate these species and other members of the family Micrococcaceae (1988) (69)
Synergism, killing kinetics, and antimicrobial susceptibility of group A and B streptococci (1981) (68)
Analysis of Ciprofloxacin Activity against Streptococcus pneumoniae after 10 Years of Use in the United States (2000) (68)
In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative. (2008) (67)
In vitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe. (2002) (65)
Acquired ability of Staphylococcus aureus to produce toxic shock-associated protein and resulting illness in a rabbit model (1985) (60)
Patterns and mechanisms of beta-lactam resistance among isolates of Escherichia coli from hospitals in the United States (1990) (60)
Cefuroxime, a New Parenteral Cephalosporin: Collaborative In Vitro Susceptibility Comparison with Cephalothin Against 5,887 Clinical Bacterial Isolates (1977) (58)
In vitro susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: a European multicenter study during 2000-2001. (2003) (58)
In vitro evaluation of HR810, a new wide-spectrum aminothiazolyl alpha-methoxyimino cephalosporin (1984) (57)
Antimicrobial Surveillance of Haemophilus influenzae in the United States during 2000-2001 Leads to Detection of Clonal Dissemination of a β-Lactamase-Negative and Ampicillin-Resistant Strain (2002) (56)
Rates of antimicrobial resistance among common bacterial pathogens causing respiratory, blood, urine, and skin and soft tissue infections in pediatric patients (2004) (55)
Problems with the Disk Diffusion Test for Detection of Vancomycin Resistance in Enterococci (1990) (55)
In Vitro Susceptibilities of Gram-Negative Bacteria Isolated from Hospitalized Patients in Four European Countries, Canada, and the United States in 2000-2001 to Expanded-Spectrum Cephalosporins and Comparator Antimicrobials: Implications for Therapy (2003) (55)
In vitro antimicrobial activity evaluation of cefodizime (HR221), a new semisynthetic cephalosporin (1981) (54)
In vitro antimicrobial spectrum, occurrence of synergy, and recommendations for dilution susceptibility testing concentrations of the cefoperazone-sulbactam combination (1987) (54)
Benchmarking the In Vitro Activities of Moxifloxacin and Comparator Agents against Recent Respiratory Isolates from 377 Medical Centers throughout the United States (2000) (53)
In vitro evaluation of CENTA, a new beta-lactamase-susceptible chromogenic cephalosporin reagent (1982) (52)
Agar disk elution method for susceptibility testing of Mycobacterium marinum and Mycobacterium fortuitum complex to sulfonamides and antibiotics (1983) (52)
Biotyping coagulase-negative staphylococci (1988) (52)
Susceptibilities to Levofloxacin in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis Clinical Isolates from Children: Results from 2000-2001 and 2001-2002 TRUST Studies in the United States (2003) (51)
Aztreonam: antibacterial activity, beta-lactamase stability, and interpretive standards and quality control guidelines for disk-diffusion susceptibility tests. (1985) (51)
Cefotaxime: in vitro activity and tentative interpretive standards for disk susceptibility testing (1980) (51)
Antimicrobial susceptibility profiles among common respiratory tract pathogens: a GLOBAL perspective. (2008) (51)
Evaluation of teicoplanin and vancomycin disk susceptibility tests (1986) (50)
Resistance Mechanisms of Multiply Resistant Pneumococci: Antibiotic Degradation Studies (1979) (50)
The development of antimicrobial resistance in staphylococci. (1988) (48)
Antimicrobial Susceptibility Patterns of Streptococcus pneumoniae (1978) (47)
In-vitro activity of cefepime and other antimicrobials: survey of European isolates. (1993) (46)
In vitro evaluation of Augmentin by broth microdilution and disk diffusion susceptibility testing: regression analysis, tentative interpretive criteria, and quality control limits (1983) (46)
Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing (1982) (45)
Antimicrobial Resistance in Respiratory Tract Pathogens: Results of an International Surveillance Study (2000) (45)
The activity of levofloxacin and other antimicrobials against clinical isolates of Streptococcus pneumoniae collected worldwide during 1999-2002. (2003) (44)
Prevalence of Oxacillin Resistance in Staphylococcus aureus among Inpatients and Outpatients in the United States during 2000 (2002) (44)
Decrease in antibiotic susceptibility or increase in resistance? (1998) (43)
The activity of a combination of penicillin and novobiocin against bovine mastitis pathogens: development of a disk diffusion test. (1997) (43)
In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin (1987) (42)
Colonization of human wounds by Escherichia vulneris and Escherichia hermannii (1985) (42)
Evaluation of the Sceptor microdilution antibiotic susceptibility testing system: a collaborative investigation (1981) (41)
Effect of culture medium and carbon dioxide concentration on growth of anaerobic bacteria commonly encountered in clinical specimens. (1974) (39)
Interpretive criteria for temocillin disk diffusion susceptibility testing (1985) (37)
Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods. (1996) (37)
Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. (2002) (37)
A gene probe for TEM type beta-lactamases (1985) (37)
Piperacillin (T-1220), a new semisynthetic penicillin: in vitro antimicrobial activity comparison with carbenicillin, ticarcillin, ampicillin, cephalothin, cefamandole and cefoxitin. (1977) (36)
Tracking resistance among bacterial respiratory tract pathogens: summary of findings of the TRUST Surveillance Initiative, 2001-2005. (2008) (36)
In vitro evaluation of A-56619 and A-56620, two new quinolones (1986) (35)
Trends in Antimicrobial Resistance Among Today's Bacterial Pathogens (1995) (35)
Cefuroxime, an in vitro Comparison with Six Other Cephalosporins (1977) (35)
Antimicrobial Susceptibility Tests for Streptococcus pneumoniae (1980) (35)
Susceptibility of multiply resistant Haemophilus influenzae to newer antimicrobial agents. (1988) (35)
Antimicrobial activity of Ro 23-9424, a novel ester-linked codrug of fleroxacin and desacetylcefotaxime (1989) (35)
Susceptibility of Clostridium botulinum to thirteen antimicrobial agents (1980) (34)
Interpretive Criteria for Antimicrobial Susceptibility Testing of Ceftiofur against Bacteria Associated with Swine Respiratory Disease (1996) (34)
Cefmenoxime (SCE-1365), a new Cephalosporin: In Vitro Activity, Comparison with Other Antimicrobial Agents, Beta-Lactamase Stability, and Disk Diffusion Testing with Tentative Interpretive Criteria (1981) (34)
Tracking the implementation of NCCLS M100-S12 expanded-spectrum cephalosporin MIC breakpoints for nonmeningeal isolates of Streptococcus pneumoniae by clinical laboratories in the United States during 2002 and 2003 (2004) (34)
Activity of pirlimycin against pathogens from cows with mastitis and recommendations for disk diffusion tests (1993) (34)
Susceptibility of clinical bacterial isolates to ciprofloxacin in the united states (1994) (33)
Chloramphenicol and penicillin resistance in pneumococci isolated from blood and cerebrospinal fluid: a prevalence study in metropolitan Denver (1983) (33)
Problems with the disk diffusion test for detection of vancomycin resistance in enterococci (1989) (32)
In vitro activity of mezlocillin and azlocillin compared with that of four other penicillins and two aminoglycosides. (1980) (32)
Apparent plateau in beta-lactamase production among clinical isolates of Haemophilus influenzae and Moraxella catarrhalis in the United States: results from the LIBRA Surveillance initiative. (2002) (30)
Activity of penicillin and three third-generation cephalosporins against US isolates of Streptococcus pneumoniae: a 1995 surveillance study. (1996) (29)
Influence of growth medium on the in vitro activities of second- and third-generation cephalosporins against Streptococcus faecalis (1984) (29)
In vitro evaluation of cefixime (FK027, FR17027, CL284635): spectrum against recent clinical isolates, comparative antimicrobial activity, beta-lactamase stability, and preliminary susceptibility testing criteria. (1986) (29)
Longitudinal Assessment of Antipneumococcal Susceptibility in the United States (2002) (29)
A comparative study of the in-vitro activity of cefepime and other antimicrobial agents against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae. (1993) (28)
BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins. (1977) (28)
Disc agar diffusion antimicrobial susceptibility tests with beta-lactamase producing Neisseria gonorrhoeae. (1978) (28)
Activities of Faropenem, an Oral β-Lactam, against Recent U.S. Isolates of Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (2002) (28)
Susceptibility of Ampicillin-Resistant Haemophilus influenzae to Seven Penicillins (1976) (28)
Antimicrobial susceptibility of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis collected from five centers in Brazil, 1997-98. (2000) (28)
Ciprofloxacin disk susceptibility tests: interpretive zone size standards for 5-microgram disks (1985) (28)
Inhibition of β-Lactamase in Neisseria gonorrhoeae by Sodium Clavulanate (1978) (27)
Antimicrobial Susceptibility of Subgingival Bacterial Flora in Cats with Gingivitis (1995) (27)
In Vitro Activities of Novel Nonfluorinated Quinolones PGE 9262932 and PGE 9509924 against Clinical Isolates of Staphylococcus aureus and Streptococcus pneumoniae with Defined Mutations in DNA Gyrase and Topoisomerase IV (2002) (27)
Ceftizoxime: collaborative multiphased in-vitro evaluation including tentative interpretive standards for disc susceptibility tests, beta-lactamase stability, and inhibition. (1982) (26)
In vitro activity of grepafloxacin and 25 other antimicrobial agents against Streptococcus pneumoniae: correlation with penicillin resistance. (1998) (26)
In vitro susceptibility of recent clinical isolates of pneumococci to the investigational cephalosporin cefditoren. (2002) (25)
RO 23-6240 (AM-833), a new fluoroquinolone: in vitro antimicrobial activity and tentative disk diffusion interpretive criteria. (1987) (25)
Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study. (2000) (25)
Rheumatic fever chemoprophylaxis and penicillin-resistant gingival organisms. (1970) (25)
Evaluation of the BIOGRAM antimicrobial susceptibility test system (1985) (25)
Preparing inoculum for susceptibility testing of anaerobes (1984) (24)
Prevalence of Acinetobacter spp. isolates with reduced susceptibility to imipenem, as determined by a USA-wide electronic surveillance network. (1999) (24)
In Vitro Evaluation of HR810, a New Wide-Spectrum Aminothiazolyl α-Methoxyimino Cephalosporin (1984) (23)
Antibiotic susceptibility of bacteria most commonly isolated from bone related infections: the role of cephalosporins in antimicrobial therapy. (2004) (23)
Antimicrobial activity of cefmetazole (CS-1170) and recommendations for susceptibility testing by disk diffusion, dilution, and anaerobic methods (1986) (23)
Ceftriaxone activity against Gram-positive and Gram-negative pathogens isolated in US clinical microbiology laboratories from 1996 to 2000: results from The Surveillance Network (TSN) Database-USA. (2002) (23)
Role of veterinary therapeutics in bacterial resistance development: animal and public health perspectives. (1998) (23)
Antimicrobial susceptibilities of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis isolated in two successive respiratory seasons in the US. (2002) (22)
Interpretation of the Disk Diffusion Susceptibility Test for Amikacin: Report of a Collaborative Study (1979) (22)
Methicillin-resistant (hetero-resistant) staphylococci (1984) (22)
Reassessment of the "class" concept of disk susceptibility testing. Cephalothin disks versus minimal inhibitory concentrations with eleven cephalosporins. (1978) (22)
Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000-2001. (2003) (22)
Proposed disk diffusion susceptibility criteria for ofloxacin (1985) (22)
Phenotypic and genotypic analysis of levofloxacin-resistant clinical isolates of Streptococcus pneumoniae collected in 13 countries during 1999-2000. (2002) (22)
Antimicrobial resistance trends among sinus isolates of Streptococcus pneumoniae in the United States (2001–2005) (2007) (22)
Disk diffusion testing, quality control guidelines, and antimicrobial spectrum of HR810, a fourth-generation cephalosporin, in clinical microbiology laboratories (1984) (22)
Variability of clarithromycin and erythromycin susceptibility tests with Haemophilus influenzae in four different broth media and correlation with the standard disk diffusion test (1988) (22)
Comparison of the antibacterial spectra of cephalexin and cefaclor with those of cephalothin and newer cephalosporins: reevaluation of the class representative concept of susceptibility testing (1983) (21)
The cefoperazone-sulbactam combination. In vitro qualities including beta-lactamase stability, antimicrobial activity, and interpretive criteria for disk diffusion tests. (1985) (21)
The Activity of Levofloxacin and Comparator Agents against Clinical Isolates of Streptococcus pneumoniae Collected Worldwide during 1999 and 2000 (2002) (21)
NCCLS Standards for Antimicrobial Susceptibility Tests (1983) (21)
Quality control limits for teicoplanin susceptibility tests and confirmation of disk diffusion interpretive criteria (1987) (21)
Gentamicin and amikacin disk susceptibility tests with Pseudomonas aeruginosa: definition of minimal inhibitory concentration correlates for susceptible and resistant categories (1981) (21)
Antimicrobial susceptibility to levofloxacin and other antibacterial agents among common respiratory pathogens-a Brazilian perspective from the GLOBAL Surveillance Initiative 2001-2002. (2004) (20)
Antimicrobial susceptibility tests with cefotaxime and correlation with clinical bacteriologic response. (1982) (20)
Review of the in vitro antibacterial activity of cefprozil, a new oral cephalosporin. (1992) (20)
Epidemiology of staphylococcal infections--a USA perspective. (1994) (20)
Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935) (1980) (20)
In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and β-lactamase studies (1985) (20)
Disk diffusion susceptibility testing of two macrolide antimicrobial agents: revised interpretive criteria for erythromycin and preliminary guidelines for roxithromycin (RU 965) (1986) (20)
Standardization of Broth Microdilution and Disk Diffusion Susceptibility Tests for Actinobacillus pleuropneumoniae and Haemophilus somnus: Quality Control Standards for Ceftiofur, Enrofloxacin, Florfenicol, Gentamicin, Penicillin, Tetracycline, Tilmicosin, and Trimethoprim-Sulfamethoxazole (2001) (20)
Vancomycin resistant streptococci? probably not (1984) (20)
Quality control limits for disk diffusion and broth microdilution susceptibility tests with Haemophilus test medium. (1991) (20)
In Vitro Activities of Broad-Spectrum Cephalosporins against Nonmeningeal Isolates of Streptococcus pneumoniae: MIC Interpretation Using NCCLS M100-S12 Recommendations (2002) (19)
In vitro antimicrobial activity of piperacillin and seven other beta-lactam antibiotics against Neisseria gonorrhoeae and Haemophilus influenzae, including beta-lactamase producing strains. (1979) (19)
Influence of cation supplements on activity of netilmicin against Pseudomonas aeruginosa in vitro and in vivo (1987) (19)
Antimicrobial activity among multidrug-resistant Streptococcus pneumoniae isolated in the United States, 2001-2005. (2008) (19)
Comparison of Four Antimicrobial Susceptibility Testing Methods To Determine the In Vitro Activities of Piperacillin and Piperacillin-Tazobactam against Clinical Isolates of Enterobacteriaceae and Pseudomonas aeruginosa (2003) (19)
Imipenem (N-formimidoyl thienamycin): in vitro antimicrobial activity and beta-lactamase stability. (1985) (19)
Methods for determining susceptibility of fastidious and unusual pathogens to selected antimicrobial agents. (1988) (18)
Evaluation of in vitro antibacterial activity of enoxacin: comparison with other orally absorbed antimicrobial agents, proposed disk diffusion test interpretive criteria, and quality control limits. (1985) (18)
Ticarcillin, carbenicillin and BL-P1908. In vitro comparison of three anti-pseudomonal semisynthetic penicillins. (1977) (18)
Selection of a reference lot of Mueller-Hinton agar (1986) (17)
Ampicillin-resistant Haemophilus influenzae. 1. Incidence, mechanism, and detection. (1982) (17)
Resistance in Respiratory Tract Pathogens: An International Study 1997–1998 (2000) (17)
Medium-dependent zone size discrepancies associated with susceptibility testing of group D streptococci against various cephalosporins (1983) (17)
Evaluation of the cefonicid disk test criteria, including disk quality control guidelines (1983) (17)
Relationship between in vitro susceptibility test results for chloramphenicol and production of chloramphenicol acetyltransferase by Haemophilus influenzae, Streptococcus pneumoniae, and Aerococcus species (1988) (17)
Interpretive standards and quality control limits for susceptibility tests with ampicillin-sulbactam combination disks (1984) (17)
Evaluation of the MicroScan antimicrobial susceptibility system with the autoSCAN-4 automated reader (1986) (16)
In vitro evaluation of LY127935 (6050S) compared with cefotaxime, eight other beta-lactams and two aminoglycosides. (1980) (16)
Compound A49759, the 3-O-demethyl derivative of fortimicin A: in vitro comparison with six other aminoglycoside antibiotics (1980) (15)
Interpretive criteria, quality control guidelines, and drug stability studies for susceptibility testing of cefotaxime, cefoxitin, ceftazidime, and cefuroxime against Neisseria gonorrhoeae. (1990) (15)
Quality control limits for microdilution susceptibility tests with aztreonam, imipenem, ceftriaxone, ceftazidime, ceftizoxime, cefuroxime, and cefonicid. (1987) (15)
Comparison of in vitro activity of Sch 21420, a gentamicin B derivative, with those of amikacin, gentamicin, netilmicin, sisomicin, and tobramycin (1980) (15)
Piperacillin susceptibility tests by the single-disk agar diffusion technique (1979) (14)
Activity of cefditoren against beta-lactamase-positive and -negative Haemophilus influenzae and Moraxella catarrhalis. (2002) (14)
Cefsulodin: antibacterial activity and tentative interpretive zone standards for the disk susceptibility test (1981) (14)
Simple inoculum standardizing system for antimicrobial disk susceptibility tests (1979) (14)
Relationship between Antibiotic Resistance in Streptococcus pneumoniae and That in Haemophilus influenzae: Evidence for Common Selective Pressure (2002) (14)
Ticarcillin: a collaborative in vitro comparison with carbenicillin against over 9,000 clinical bacterial isolates (1977) (13)
Rapid determination of minimum inhibitory concentrations of antimicrobial agents by the Autobac method: a collaborative study (1980) (13)
Evaluating the in vitro susceptibility of bovine mastitis pathogens to a combination of kanamycin and cefalexin: Recommendations for a disk diffusion test. (2009) (13)
Antibacterial activity of trospectomycin (U-63366F) and initial evaluations of disk diffusion susceptibility tests (1989) (13)
Cefoperazone: evaluation of the in vitro activity and an analysis of the disk diffusion test. (1980) (13)
Tentative interpretive standards for agar disk diffusion antimicrobial susceptibility testing of cefoperazone (1982) (13)
Emerging resistance in clinically important gram-positive cocci. (1996) (12)
Effect of media and blood on the antimicrobial activity of cephalosporins on serogroup D streptococci: a review. (1984) (12)
In Vitro Activity of Rosamicin, Josamycin, Erythromycin, and Clindamycin Against β-Lactamase-Negative and β-Lactamase-Positive Strains of Neisseria gonorrhoeae (1979) (12)
Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits (1982) (12)
Antimicrobial susceptibility testing of anaerobic bacteria: review and update on the role of the National Committee for Clinical Laboratory Standards. (1990) (12)
Interpretive Criteria for Cefamandole and Cephalothin Disk Diffusion Susceptibility Tests (1979) (12)
Tentative disk diffusion susceptibility interpretive criteria for BMY-28142, a new cephalosporin (1986) (12)
Determination of the ascorbic acid content of two medicinal plants in Nigeria. (2006) (12)
Piperacillin (T-1220), a new semisynthetic penicillin. II. In vitro antimicrobial activity and synergy comparison with carbenicillin and gentamicin. (1979) (11)
BL-S786, A NEW PARENTERAL CEPHALOSPORIN. I (1977) (11)
Antimicrobial Resistance Among Escherichia coli Urinary Tract Isolates in the United States: A Current View Provided by Electronic Surveillance (2001) (11)
Interpretive standards for disk susceptibility tests with Sch 21420 and amikacin (1980) (11)
Agar Dilution and Disk Diffusion Susceptibility Testing of Campylobacter spp. (2007) (11)
Activity of faropenem, a new furanem, against European respiratory pathogens collected during 2000-2001: a comparison with other beta-lactam agents. (2003) (10)
Antimicrobial Susceptibility of Subgingival Bacterial Flora in Dogs with Gingivitis (1995) (10)
Ceftriaxone: A summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-μg disks (1983) (10)
Modification of interpretive breakpoints for netilmicin disk susceptibility tests with Pseudomonas aeruginosa (1984) (10)
Cefaclor and cefatrizine, new investigational orally administered cephalosporins. In-vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics. (1979) (10)
Antimicrobial resistance in respiratory pathogens isolated in Brazil during 1999-2000. (2001) (9)
Temocillin: in vitro activity against 734 selected clinical isolates, including beta-lactamase-producing strains. (1984) (9)
Antimicrobial Susceptibility of Five Subgroups of Mycobacterium fortuitum and Mycobacterium chelonae (1986) (9)
Antimicrobial resistance in Haemophilus influenzae: a global perspective. (1988) (9)
Cefuroxime, cefamandole, cefoxitin, and cephalothin in vitro susceptibility tests: reassessment of the "class representative" concept, confirmation of disk interpretive criteria, and proposed quality control guidelines. (1983) (9)
Evaluation of the MICUR system for quantitative antimicrobial susceptibility testing: a multiphasic comparison with reference methods (1982) (9)
Sch 29482, a new oral penem: comparative in-vitro activity, beta-lactamase stability and inhibition. (1982) (9)
Susceptibility of Xanthomonas (Pseudomonas) Maltophilia to antimicrobial agents: Methodological Problems (1989) (9)
Evaluation ofTeicoplanin andVancomycin DiskSusceptibility Tests (1986) (8)
Tentative disk diffusion susceptibility interpretive criteria for pefloxacin (1986) (8)
Rosamicin: in vitro activity comparison with erythromycin and other antibiotics against clinical isolates from the genito-urinary tract and Neisseria meningitidis. (1979) (8)
Quality control limits for the standard anaerobic reference agar dilution susceptibility test procedure of the National Committee for Clinical Laboratory Standards (1989) (8)
Disk Diffusion Susceptibility Test Troubleshooting Guide (1984) (8)
Antibacterial activity of fortimicin A compared with those of five other aminoglycosides, and factors affecting susceptibility tests (1981) (8)
BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates. (1977) (8)
Cefaclor AF: correlation of microbiology and clinical outcome. (1992) (7)
Factors influencing fluoroquinolone resistance. (2003) (7)
Quality control parameters and interpretive criteria for in vitro susceptibility tests with the macrolide azithromycin (1989) (7)
Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Review, Comments, and Opinions (1991) (7)
The re-evaluation of the NCCLS ampicillin susceptibility tests with Haemophilus test medium: New interpretive criteria for the disk diffusion method (1992) (7)
Cefpirome (HR810) disk diffusion susceptibility tests: confirmation of interpretive criteria using cefotaxime and cefoperazone-resistant strains and effects of blood supplemented media. (1986) (7)
Disk diffusion susceptibility testing ofHaemophilus influenzae using Haemophilus test medium (1990) (7)
Inhibition of beta-lactamase in Neisseria gonorrhoeae by sodium clavulanate. (1978) (7)
Antimicrobial susceptibility testing systems past and present: A documented overview. Part II (1985) (7)
Comparative Activity of Cefditoren and Other Oral β-Lactams against Nonpneumococcal Streptococci (2001) (7)
Gentamicin, tobramycin, and sisomicin disc susceptibility tests. Revised zone standards for interpretation. (1981) (7)
The anti-microbial activity, beta-lactamase stability, and disk diffusion susceptibility testing of carumonam (RO 17-2301, AMA-1080), a new monobactam. (1986) (7)
The In Vitro Antibacterial Activity of Quinolones: A Review (1998) (7)
The application of information technology to regional, national, and global surveillance of antimicrobial resistance. (2003) (7)
Inter- and intralaboratory variability in antibiotic susceptibility tests with Pseudomonas aeruginosa and Enterobacteriaceae. (1976) (6)
THE SURVEILLANCE NETWORK (TSN) : A POWERFUL WEAPON IN THE FIGHT AGAINST ANTIBIOTIC RESISTANCE (1998) (6)
Interpretive standards and quality control guidelines for imipenem susceptibility tests with 10-micrograms disks (1984) (6)
Cefpiramide: comparative in-vitro activity and β-lactamase stability (1985) (6)
Antimicrobial Resistance among Respiratory Pathogens Collected in Thailand during 1999-2000 (2002) (6)
In-vitro activity of the penem, FCE 22101, and tentative interpretive criteria for disc susceptibility tests. (1989) (6)
Susceptibility tests for sulfamethoxazole-trimethoprim by a broth microdilution procedure (2007) (6)
Microplate phosphocellulose binding assay for aminoglycoside-modifying enzymes (1986) (6)
Determining Linezolid’s Baseline In Vitro Activity in Canada Using Gram-Positive Clinical Isolates Collected prior to Its National Release (2002) (6)
Disk agar diffusion susceptibility testing with 30-micrograms ceftazidime disks: confirmation of interpretive breakpoints and quality control guidelines (1983) (6)
Levofloxacin-Resistant Streptococcus pneumoniae: Second Look (2001) (5)
Cefotiam susceptibility testing criteria (1985) (5)
Susceptibility testing of fastidious and unusual pathogens (1987) (5)
Calcium and magnesium in Mueller-Hinton agar and their influence on disk diffusion susceptibility results (1979) (5)
In-vitro bactericidal synergism of rifampicin and trimethoprim and implications for treatment of carriers of Haemophilus influenzae. (1982) (5)
General Guidelines for Clinical Bacteriology (1992) (5)
Mechanism of aminoglycoside resistance among beta-lactam-resistant Escherichia coli in the United States. (1987) (5)
Commercial detection methods for biotinylated gene probes: Comparison with32P-labeled DNA probes (1986) (5)
Resistance in respiratory tract pathogens: an international study 1997-1998. (2000) (5)
DNA hybridization studies of a nucleotide sequence homologous to transposon Tn1545 in the "Minnesota" strain of multiresistant Streptococcus pneumoniae isolated in 1977. (1989) (5)
Trends in Ciprofloxacin Nonsusceptibility and Levofloxacin Resistance among Streptococcus pneumoniae Isolates in North America (2001) (5)
Mezlocillin: tentative interpretive standards for disk diffusion susceptibility testing (1981) (5)
Disk diffusion susceptibility testing of ticarcillin plus clavulanic acid (1984) (5)
Azlocillin, a ureido penicillin active against Pseudomonas aeruginosa: interpretive zone standards and quality control parameters for tests with 75-mu g disks (1982) (5)
β-Lactamase of the Legionnaires' bacterium (2007) (5)
Penicillin-resistant Streptococcus pneumoniae on the rise in the United States: Its effect on oral cephalosporins (1994) (4)
Evaluation oftheInVitro Activity ofBMY-28142, aNew Broad- Spectrum Cephalosporin (1985) (4)
Techniques for anaerobic susceptibility testing. (1977) (4)
Quality control limits for microdilution susceptibility tests with norfloxacin (1987) (4)
Gram-positive superinfections: A consequence of modern β-lactam chemotheraphy (1985) (4)
The in vitro activity of sulphones alone and in combination with ampicillin or amoxicillin against Legionella pneumophila and other Legionella spp. including beta-lactamase studies. (1985) (4)
Reinterpretation of Susceptibility Data Using Current NCCLS Breakpoint Criteria (2003) (4)
Interlaboratory variability of disc diffusion and agar dilution susceptibility tests with cefamandole and cephalothin (1978) (3)
Quality control guidelines for testing cefotetan in the reference agar dilution procedure for susceptibility testing of anaerobic bacteria (1989) (3)
A survey of ciprofloxacin and 11 other antimicrobial agent susceptibility data of United States bacterial isolates from 1990 to 1992 (1995) (3)
Interpretive criteria and tentative quality control limits for apalcillin disk susceptibility tests (1984) (3)
Antibacterial Activities ofCiprofloxacin, Norfloxacin, Oxolinic Acid, Cinoxacin, andNalidixic Acid (1984) (3)
Apalcillin (PC-904): Spectrum of activity and β-lactamase hydrolysis/inhibition (1985) (3)
β-Lactam antibiotics: The first- and second-generation cephalosporins (1985) (3)
Cefpiramide: comparative in-vitro activity and beta-lactamase stability. (1985) (3)
In-vitro evaluation of Sen 34343: antimicrobial activity, β-lactamase stability and inhibition (1985) (3)
In vitro antimicrobial activity of cefoperazone-sulbactam combinations against 554 clinical isolates including a review and beta-lactamase studies. (1985) (3)
CI-934, a new difluoroquinolone: in vitro antibacterial activity and proposed disk diffusion test interpretive criteria. (1987) (3)
Evaluation of the Bactrol Disks, a Set of Quality Control Cultures (1975) (2)
Antimicrobial resistance in pneumococci from the USA: Are there trends? (1988) (2)
Analysis of Levofloxacin and Comparator Antibiograms against Urinary Tract Infection (UTI) Isolates of E. coli and Other Enterobacteriaceae Across the United States (2007) (2)
Current Activity of Ciprofloxacin Against Gram-Negative Bacilli in the United States (1999) (2)
Cefotaxime: InVitro Activity andTentative Interpretive Standards forDiskSusceptibility Testing (1980) (2)
Letter: The disc sensitivity test. (1975) (2)
Antimicrobial Susceptibility Patterns ofCommonandUnusual Species ofEnterococci Causing Infections intheUnited States (1992) (2)
Successful UseofBrothMicrodilution inSusceptibility Tests forMethicillin-Resi stant (Heteroresistant ) Staphylococci (1983) (2)
In-vitro activities of cefamandole and cephalothin against 1,881 clinical isolates. A multi-center study. (1979) (2)
In vitro antimicrobial susceptibility testing using 30 μG and 75 μG U63196-E (cefpimizole AC-1370) disks (1985) (2)
Bacterial respiratory infections: a review of the problems of etiology and antimicrobial susceptibility testing. (1973) (2)
Antimicrobial susceptibility tests for anaerobic bacteria. Comparison of Wilkins-Chalgren agar reference method and a microdilution method, and determination of stability of antimicrobics frozen in broth (1978) (2)
Effect of Culture Medium and Carbon Dioxide Concentration on Growth of Anaerobic Bacteria Commonly Encountered in Clinical Specimens (1974) (2)
Antimicrobial Susceptibility ofFiveSubgroups ofMycobacterium fortuitum andMycobacterium chelonae (1985) (2)
Proposed zone standards for interpretation of fortimicin A disk diffusion tests (1983) (2)
Disk diffusion and disk elution tests with A-56268 and erythromycin (1987) (2)
Antimicrobial Susceptibility Tests: Automation and Mechanization (1985) (2)
What's in a name?: More on methicillin (or is it oxacillin?)-resistant staphylococci (1986) (2)
InVitro Antimicrobial Spectrum, Occurrence ofSynergy, and Recommendations forDilution Susceptibility Testing Concentrations oftheCefoperazone-Sulbactam Combination (1987) (2)
Reliability of cefaclor, cefazolin, cefamandole, and cephalothin disks to predict susceptibility of Enterobacteriaceae, Staphylococcus species, and Haemophilus influenzae. (1985) (2)
Current Susceptibility Patterns for Streptococcus pneumoniae Isolates from Europe and Asia: Findings of the 2007 GLOBAL Surveillance Program (2008) (1)
Cefoperazone: Spectrum of Antibacterial Activity and Disc Diffusion Testing (2012) (1)
In-vitro evaluation of Sch 34343: antimicrobial activity, beta-lactamase stability and inhibition. (1985) (1)
Unusual patterns of aminoglycoside resistance in Pseudomonas aeruginosa (1984) (1)
In vitro activity of DJ-6783 (a keto carboxylic acid) compared with six other orally administered antimicrobial agents. (1986) (1)
Ampicillin-resistant Haemophilus influenzae. 2. Therapeutic considerations. (1982) (1)
β-lactam antibiotics: The original and penicillinase-resistant penicillins (1985) (1)
In vitro Inhibition of Migration of Leukocytes by Old Tuberculin (OT) as an Indicator of Active Tuberculosis. (1964) (1)
Susceptibility ofAmpicillin-Resis tant Haemophilus influenzae toSevenPenicillins (1976) (1)
1-N-(S-3-amino-2-hydroxypropionyl) gentamicin B (Sch 21420): A collaborative in vitro susceptibility comparison with amikacin and gentamicin against 12,984 clinical bacterial isolates (1978) (1)
Susceptibility testing of Haemophilus influenzae: Some good news—some not so good (1985) (1)
Quality control of moxalactam susceptibility disks (1983) (1)
Interpretive standards of cefbuperazone disk diffusion susceptibility tests (1985) (1)
Surveillance of Antimicrobial Resistance among Respiratory Tract Pathogens in the United States, 1997 to 1998 (1999) (1)
In vitro activity of the aryl-fluoroquinolones A-56619 and A-56620 and evaluation of disk susceptibility tests (1986) (1)
Longitudinal Analysis of Tigecycline Activity against US isolates of Enterobacteriaceae and Acinetobacter spp. Based on Patient Location and Specimen Source (2008) (1)
Tentative interpretive criteria for the diffusion susceptibility test using 30-microgram netilmicin disks (1980) (1)
Ceftriaxone: a summary of in vitro antibacterial qualities including recommendations for susceptibility tests with 30-micrograms disks. (1983) (1)
The Activity of Fluoroquinolones and Other Antimicrobial Agents Against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis (1999) (1)
ANTIMICROBIAL SUSCEPTIBILITIES OF ENTEROBACTERIACEAE (EB) AND PSEUDOMONAS AERUGINOSA (PA) FROM INPATIENT INFECTIONS IN THE U.S.: 1999-2002 TRUST SURVEILLANCE: 483 (2002) (1)
Activity ofPirlimycin against Pathogens fromCowswith Mastitis andRecommendations forDiskDiffusion Tests (1993) (1)
Chloramphenicol susceptibility testing of Haemophilus influenzae (1987) (1)
General guidelines for clinical bacteriology. Infectious Diseases Society of America and the Food and Drug Administration. (1992) (1)
Influence ofCation Supplements on Activity ofNetilmicin against Pseudomonas aeruginosa InVitro andInVivo (1987) (0)
Evaluation oftheBactrol Disks, a SetofQuality Control Cultures (1975) (0)
Netilmicin disk susceptibility tests: Effect of cations on the MIC correlates (1987) (0)
β-lactam antibiotics: The extended spectrum penicillins (1985) (0)
P737 Current susceptibility patterns for Streptococcus pneumoniae and Haemophilus infiuenzae isolates from Europe: findings of the 2005–2006 GLOBAL Surveillance Program (2007) (0)
Antimicrobial susceptibility testing of nonenterococcal streptococci (1986) (0)
Amikacin Gentamicin Netilmicin Sisomicin Tobramycin Fortimicin A Amikacin Gentamicin Netilmicin Sisomicin Tobramycin Fortimicin A Amikacin Gentamicin Netilmicin Sisomicin Tobramycin Fortimicin A Amikacin Gentamicin Netilnicin Sisomicin Tobramycin Fortimicin A Amikacin Gentamicin Netilmicin Sisomicin (0)
Broth Agar Broth Agar Broth Agar Broth Agar Broth Agar Broth Agar Broth ' Agar Broth Agarc Broth Agar Broth Agar Broth Agar Broth Agar Broth Agar Broth Agar Broth Agar Broth Agar Broth Agarc Broth Agar Broth Agar (0)
Variability ofClarithromycin andErythromycin Susceptibility Tests withHaemophilus influenza inFourDifferent BrothMediaand Correlation withtheStandard DiskDiffusion Test (1988) (0)
Current Opinion in the Treatment of Community-Acquired Pneumonia: Results of the Presymposium Interactive Question and Answer Session (2000) (0)
Comparative Susceptibility Patterns of Levofloxacin and Other Agents against Pediatric Respiratory Tract Isolates of Streptococcus pneumoniae (SP) (2006) (0)
/3-Lactamase of the Leglonnmre Bacterium (1978) (0)
Activity of ceftriaxone and comparator agents against bacterial pathogens isolated from central nervous system (CNS) (meningeal) specimens: TSN Database USA 2000–2002 (2003) (0)
Susceptibility to Cephalosporins and Fluoroquinolones among Enterobacteriaceae Isolated From Lower Respiratory Tract Infections (TSN Database-USA, 1998–2002): Implications for Empiric Therap (2003) (0)
CAP survey on an anaerobe—a little good news (1985) (0)
Interpretive Standards andQuality Control Guidelines forImipenem Susceptibility Tests with10-Vig Disks (1984) (0)
P2024 Profile of ceftobiprole activity against S. aureus, S. pneumoniae, Enterobacteriaceae, and P. aeruginosa: results of the 2005–2006 Surveillance Program (2007) (0)
3-0-demethyl fortimicin A: In vitro activity and interpretive zone standards for disk diffusion susceptibility tests (1984) (0)
P823 Europe surveillance initiative profiling the activity of telavancin against streptococci by specimen source from 2004 to 2005 (2007) (0)
Methods of measuring susceptibility of anaerobic bacteria to trovafloxacin, including quality control parameters (1996) (0)
Ceftobiprole (BPR) Activity against MRSA Stratified According to Patient Population and Specimen Source; Results of the Recent TRUST Surveillance Initiative (2007) (0)
In vitro activity of imipenem ± aminoglycosides against Pseudomonas aeruginosa and Acinetobacter calcoaceticus / baumanii isolated from patients in ICUs in German hospitals (1999–2002) (2003) (0)
Problems withtheDiskDiffusion TestforDetection ofVancomycin Resistance inEnterococci (1989) (0)
DiskDiffusion Susceptibility Testing ofTicarcillin PlusClavulanic Acid (1984) (0)
The health and management of poultry production. Discussion (2002) (0)
Fluoroquinolone Susceptibility Profiles of Recent Urinary Tract Isolates Obtained from Pediatric Patients (2006) (0)
International Surveillance of Susceptibility to Levofloxacin and Other Agents among Respiratory Pathogens (1999) (0)
Susceptibility of Gram-negative bacteria to β-lactam antibiotics and rapid characterization of β-lactamase activity (1979) (0)
P2046 Analysis of tigecycline activity against Acinetobacter spp. and Enterobacteriaceae based on clinical specimen source (2007) (0)
P1664 Baseline surveillance profile of doripenem against key Gram-negative pathogens encountered in Europe (2007) (0)
Proposed Quality Control Guidelines (2016) (0)
P824 Europe surveillance initiative profiling the anti-staphylococcal activity of telavancin by specimen source from 2004 to 2005 (2007) (0)
Methods ofMeasuring ZonesofInhibition withtheBauer- KirbyDiskSusceptibility Test (1979) (0)
InVitro Activity ofa NewMacrolide, A-56268, Compared withThat ofRoxithromycin, Erythromycin, andClindamycin (1987) (0)
Antimicrobial Susceptibility of Five Subgroups of and. (1986) (0)
Regional Prevalence of and Analysis of Ceftobiprole Activity Against MRSA from 2006 to 2008 TRUST Surveillance and TSN Data (2009) (0)
Invitro activity of levofloxacin against contemporary clinical isolates of Legionella pneumophila, Mycoplasma pneumoniae and Chlamydia pneumoniae from North America and Europe (2014) (0)
In vitro antimicrobial susceptibility testing using 30 microG and 75 microG U63196-E (cefpimizole AC-1370) disks. (1985) (0)
Consensus among Participants for the Treatment of Community-Acquired Pneumonia: Results of the Postsymposium Interactive Question and Answer Session (2000) (0)
Recommendations for susceptibility tests with Rifampin—at last! (1988) (0)
InVitro Antimicrobial Activity Evaluation ofCefodizime (HR221), aNewSemisynthetic Cephalosporin (1981) (0)
Antimicrobial Activity ofRo23-9424, aNovelEster-Linked Codrug ofFleroxacin andDesacetylcefotaxime (1989) (0)
Susceptibility of H. influenzae and M. catarrhalis in Asia and Europe: 2007 GLOBAL Surveillance Program (2008) (0)
Characteristics ofCoagulase-Negative Staphylococci ThatHelp Differentiate TheseSpecies andOtherMembers oftheFamily Micrococcaceae (1988) (0)
β-lactam antibiotics: The third-generation cephalosporins and other newer β-lactams (1985) (0)
Apalcillin [PC-904]: spectrum of activity and beta-lactamase hydrolysis/inhibition. (1985) (0)
Prevalence of Multi-drug Resistant (MDR) Streptococcus pneumoniae (SP) and Relative Activities of Levofloxacin (2004) (0)
Antimicrobal susceptibility testing of Listeria (1985) (0)
NCCLS subcommittee members respond: To “Critical reflections on current problems associated with susceptibility testing and monitoring of antimicrobial therapy” (1987) (0)
R2156 Analysis of tigecycline activity against Staphylococcus aureus based on clinical specimen source (2007) (0)
Interpretive Standards andQuality Control Limits forSusceptibility TestswithAmpicillin-Sulba ctam Combination Disks (1984) (0)
Interpretive Standards andQuality Control Guidelines for Cefpiramide DiskSusceptibility Tests (1985) (0)
Cefuroxime, Cefamandole, Cefoxitin, and Cephalothin In Vitro Susceptibility Tests: Reassessment of the"Class Representative" Concept, Confirmation of Disk Interpretive Criteria, and Proposed Quality Control Guidelines (1984) (0)
Antimicrobial activity of LY164846, a new oral cephalosporin, and recommendations for disk diffusion tests. (1987) (0)
Interpretive standards and quality control guidelines for cefpiramide disk susceptibility tests (1985) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Clyde Thornsberry?

Clyde Thornsberry is affiliated with the following schools:

Mercer University

Clyde Thornsberry's Academic­Influence.com Rankings

Clyde Thornsberry's Degrees

Why Is Clyde Thornsberry Influential?

Clyde Thornsberry's Published Works

Published Works

What Schools Are Affiliated With Clyde Thornsberry?

Clyde Thornsberry's AcademicInfluence.com Rankings